PL2604610T3 - Pochodna ketonu ftalazynonowego, sposób jej wytwarzania oraz jej farmaceutyczne zastosowanie - Google Patents
Pochodna ketonu ftalazynonowego, sposób jej wytwarzania oraz jej farmaceutyczne zastosowanieInfo
- Publication number
- PL2604610T3 PL2604610T3 PL11815986.2T PL11815986T PL2604610T3 PL 2604610 T3 PL2604610 T3 PL 2604610T3 PL 11815986 T PL11815986 T PL 11815986T PL 2604610 T3 PL2604610 T3 PL 2604610T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- pharmaceutical use
- ketone derivative
- phthalazinone
- phthalazinone ketone
- Prior art date
Links
- -1 Phthalazinone ketone Chemical class 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102483075A CN102372716A (zh) | 2010-08-09 | 2010-08-09 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2604610T3 true PL2604610T3 (pl) | 2016-11-30 |
Family
ID=45567315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11815986.2T PL2604610T3 (pl) | 2010-08-09 | 2011-07-26 | Pochodna ketonu ftalazynonowego, sposób jej wytwarzania oraz jej farmaceutyczne zastosowanie |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9273052B2 (enExample) |
| EP (1) | EP2604610B1 (enExample) |
| JP (1) | JP5808408B2 (enExample) |
| KR (1) | KR101829940B1 (enExample) |
| CN (2) | CN102372716A (enExample) |
| AU (1) | AU2011288876B2 (enExample) |
| BR (1) | BR112013002220B1 (enExample) |
| CA (1) | CA2806324C (enExample) |
| ES (1) | ES2582315T3 (enExample) |
| HU (1) | HUE029275T2 (enExample) |
| PL (1) | PL2604610T3 (enExample) |
| PT (1) | PT2604610T (enExample) |
| RU (1) | RU2564527C2 (enExample) |
| UA (1) | UA111161C2 (enExample) |
| WO (1) | WO2012019427A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
| CN102702108A (zh) * | 2012-06-27 | 2012-10-03 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
| CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| CN102863393A (zh) * | 2012-09-26 | 2013-01-09 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
| DK2938598T3 (en) * | 2012-12-31 | 2017-02-13 | Cadila Healthcare Ltd | Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
| ES2879434T3 (es) | 2015-07-23 | 2021-11-22 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
| EP3377493B1 (en) | 2015-11-20 | 2020-04-08 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| CN106749261A (zh) | 2015-11-23 | 2017-05-31 | 中国科学院上海药物研究所 | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 |
| CN107207504B (zh) * | 2015-12-16 | 2020-03-10 | 四川科伦博泰生物医药股份有限公司 | 酞嗪酮衍生物、其制备方法及用途 |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| CN108778336A (zh) * | 2016-12-01 | 2018-11-09 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂与parp抑制剂联合在制备治疗胃癌的药物中的用途 |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3680241A1 (en) | 2017-03-20 | 2020-07-15 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| WO2018191389A1 (en) * | 2017-04-12 | 2018-10-18 | Roche Sequencing Solutions, Inc. | A method for sequencing reaction with tagged nucleoside obtained via pictet spengler reaction |
| US11180505B2 (en) | 2017-08-24 | 2021-11-23 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal form of PARP-1 inhibitor and preparation method therefor |
| CN111093706B (zh) * | 2017-12-06 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途 |
| CN111278830B (zh) * | 2018-01-09 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 一种parp抑制剂及其中间体的制备方法 |
| PH12020500600B1 (en) * | 2018-01-26 | 2023-12-06 | Recordati Ind Chimica E Farmaceutica S P A | Triazole, imidazole and pyrrole condensed piperazine derivatives and their use as modulators of mglu5 receptors |
| CA3129516A1 (en) | 2018-02-28 | 2019-09-06 | The Trustees Of The University Of Pennsylvania | Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| AU2019245403B2 (en) * | 2018-03-29 | 2025-02-06 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
| CN112584836A (zh) * | 2018-10-22 | 2021-03-30 | 江苏恒瑞医药股份有限公司 | 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途 |
| US12318385B2 (en) | 2018-11-16 | 2025-06-03 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising PARP inhibitors |
| WO2020238932A1 (zh) * | 2019-05-28 | 2020-12-03 | 江苏恒瑞医药股份有限公司 | Parp抑制剂联合vegfr抑制剂用于治疗卵巢癌或乳腺癌的用途 |
| HUE072832T2 (hu) | 2019-09-19 | 2025-12-28 | Novo Nordisk Healthcare Ag | Piruvát kináz R-t (PKR) aktiváló készítmények |
| CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12060345B2 (en) | 2020-04-21 | 2024-08-13 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| CA3176219A1 (en) | 2020-04-21 | 2021-10-28 | Kunhee LEE | Crystalline forms of phthalazinone compound |
| CN111732594B (zh) * | 2020-08-18 | 2022-03-04 | 苏州富士莱医药股份有限公司 | 一种氟唑帕利的制备方法 |
| CN116348112A (zh) | 2020-10-02 | 2023-06-27 | 德州大学系统董事会 | 转录激活蛋白的咪唑并哌嗪抑制剂 |
| JP2023544173A (ja) | 2020-10-02 | 2023-10-20 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| US20240287094A1 (en) * | 2021-05-24 | 2024-08-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines |
| US20240317762A1 (en) * | 2021-07-16 | 2024-09-26 | Oregon Health & Science University | Phthalazinone-based parp-1 inhibitors |
| WO2023006013A1 (zh) * | 2021-07-29 | 2023-02-02 | 上海齐鲁制药研究中心有限公司 | 新型parp7抑制剂及其应用 |
| CN115650988B (zh) * | 2022-10-27 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 一种parp抑制剂的制备方法 |
| AU2023383898A1 (en) * | 2022-11-23 | 2025-06-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt of nitrogen-containing heterocyclic compound, crystal form thereof, and preparation method therefor |
| WO2024188265A1 (zh) * | 2023-03-13 | 2024-09-19 | 江苏豪森药业集团有限公司 | 哌啶烯类化合物在制备治疗癌症的药物中的应用 |
| CN121398822A (zh) | 2023-06-21 | 2026-01-23 | 四方生物科学有限公司 | 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9578901A (en) | 2000-10-30 | 2002-05-15 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7402580B2 (en) * | 2002-02-19 | 2008-07-22 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
| AR043443A1 (es) | 2003-03-07 | 2005-07-27 | Merck & Co Inc | Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios |
| GB0305681D0 (en) * | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| AU2004220321B2 (en) * | 2003-03-12 | 2010-02-25 | Kudos Pharmaceuticals Ltd | Phthalazinone derivatives |
| EP1791827A1 (en) | 2004-08-26 | 2007-06-06 | Kudos Pharmaceuticals Limited | 4-heteroarylmethyl substituted phthalazinone derivatives |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| PT2698062E (pt) * | 2006-12-28 | 2015-10-19 | Abbvie Inc | Inibidores da poli (adp-ribose) polimerase |
| US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| JP5313246B2 (ja) | 2007-08-21 | 2013-10-09 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としてのヘテロシクリル化合物 |
| CN101468988A (zh) | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| WO2009090055A1 (en) | 2008-01-17 | 2009-07-23 | Grünenthal GmbH | Substituted sulfonamide derivatives |
-
2010
- 2010-08-09 CN CN2010102483075A patent/CN102372716A/zh active Pending
-
2011
- 2011-07-26 RU RU2013106754/04A patent/RU2564527C2/ru active
- 2011-07-26 US US13/811,957 patent/US9273052B2/en active Active
- 2011-07-26 PL PL11815986.2T patent/PL2604610T3/pl unknown
- 2011-07-26 EP EP11815986.2A patent/EP2604610B1/en active Active
- 2011-07-26 UA UAA201301524A patent/UA111161C2/uk unknown
- 2011-07-26 PT PT118159862T patent/PT2604610T/pt unknown
- 2011-07-26 BR BR112013002220-5A patent/BR112013002220B1/pt active IP Right Grant
- 2011-07-26 WO PCT/CN2011/001223 patent/WO2012019427A1/zh not_active Ceased
- 2011-07-26 ES ES11815986.2T patent/ES2582315T3/es active Active
- 2011-07-26 CN CN201180003990.9A patent/CN102686591B/zh active Active
- 2011-07-26 CA CA2806324A patent/CA2806324C/en active Active
- 2011-07-26 HU HUE11815986A patent/HUE029275T2/en unknown
- 2011-07-26 KR KR1020137003185A patent/KR101829940B1/ko active Active
- 2011-07-26 JP JP2013523468A patent/JP5808408B2/ja active Active
- 2011-07-26 AU AU2011288876A patent/AU2011288876B2/en active Active
-
2016
- 2016-02-05 US US15/016,986 patent/US9566277B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20130131068A1 (en) | 2013-05-23 |
| CN102372716A (zh) | 2012-03-14 |
| RU2013106754A (ru) | 2014-09-20 |
| CN102686591B (zh) | 2014-03-19 |
| US20160151367A1 (en) | 2016-06-02 |
| AU2011288876A2 (en) | 2013-02-21 |
| RU2564527C2 (ru) | 2015-10-10 |
| JP5808408B2 (ja) | 2015-11-10 |
| WO2012019427A8 (zh) | 2012-05-10 |
| CA2806324C (en) | 2019-02-19 |
| AU2011288876A1 (en) | 2013-01-31 |
| EP2604610A1 (en) | 2013-06-19 |
| KR101829940B1 (ko) | 2018-02-19 |
| UA111161C2 (uk) | 2016-04-11 |
| HK1174030A1 (en) | 2013-05-31 |
| JP2013535491A (ja) | 2013-09-12 |
| CA2806324A1 (en) | 2012-02-16 |
| BR112013002220A2 (pt) | 2016-05-24 |
| ES2582315T3 (es) | 2016-09-12 |
| EP2604610B1 (en) | 2016-05-11 |
| AU2011288876B2 (en) | 2014-08-21 |
| CN102686591A (zh) | 2012-09-19 |
| WO2012019427A1 (zh) | 2012-02-16 |
| KR20130110149A (ko) | 2013-10-08 |
| EP2604610A4 (en) | 2013-12-25 |
| US9273052B2 (en) | 2016-03-01 |
| BR112013002220B1 (pt) | 2021-09-21 |
| US9566277B2 (en) | 2017-02-14 |
| HUE029275T2 (en) | 2017-02-28 |
| PT2604610T (pt) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2604610T (pt) | Derivado cetona de ftalazinona, processo para a sua preparação e seu uso farmacêutico | |
| ZA201300100B (en) | Indolizine derivatives,process for the preparation thereof and therapeutic use thereof | |
| PL2573073T3 (pl) | Pochodne pirazolochinolinonu, ich wytwarzanie i ich zastosowanie terapeutyczne | |
| PL2792497T3 (pl) | Elementy zabezpieczające i sposoby ich wytwarzania | |
| SG2014012488A (en) | Multiple drug infusion system and method | |
| ZA201209632B (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| EP2481739A4 (en) | DIHYDROPTERIDINONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL USE | |
| ZA201404625B (en) | Polycyclic derivatives, preparation method and medical uses thereof | |
| ZA201300685B (en) | Anticancer derivatives,preparation thereof and therapeutic use thereof | |
| SI2655375T1 (sl) | Derivati pirimidinona, njihova priprava in njihova farmacevtska uporaba | |
| IL225972A0 (en) | Salts of cocuamine b, a method for their preparation and use | |
| ZA201400188B (en) | Substituted cinnamamide derivative, preparation method and use thereof | |
| AP2012006526A0 (en) | Germination-stimulant carbamate derivatives and process for preparation thereof | |
| EP2924042A4 (en) | BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| IL233238A0 (en) | Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use | |
| ZA201309559B (en) | Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof | |
| IL239146A0 (en) | Aminocyclobutane derivatives, methods for their preparation and their use as drugs | |
| ZA201206740B (en) | Aildenafil citrate crystal form o,preparation method and use thereof | |
| EP2604605A4 (en) | THEANINE DERIVATIVE, PROCESS FOR THE PREPARATION AND USE AGAINST ACNE | |
| EP2610257A4 (en) | DIIMIDED DERIVATIVE OF BERBAMINE, MANUFACTURING METHOD AND ITS USE | |
| EP2786989A4 (en) | 2-ALKYL OR ARYL-SUBSTITUTED TANSHINONE DERIVATIVES, METHOD OF MANUFACTURING THEREOF AND THE APPLICATION THEREOF | |
| EP2626347A4 (en) | DALFAMPRIDINPOLYMORPH AND THE PREPARATION AND USE THEREOF | |
| IL214544A0 (en) | Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof | |
| EP2621490A4 (en) | PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | |
| EP2616120A4 (en) | ADMINISTRATION APPARATUS, METHOD OF OPERATION THEREFOR, AND METHOD OF ADMINISTRATION |